436 related articles for article (PubMed ID: 27987231)
1. Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
Senek M; Nielsen EI; Nyholm D
Mov Disord; 2017 Feb; 32(2):283-286. PubMed ID: 27987231
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
[TBL] [Abstract][Full Text] [Related]
3. Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
Nausieda PA; Hsu A; Elmer L; Gil RA; Spiegel J; Singer C; Khanna S; Rubens R; Kell S; Modi NB; Gupta S
J Parkinsons Dis; 2015; 5(4):837-45. PubMed ID: 26444090
[TBL] [Abstract][Full Text] [Related]
4. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
Kuoppamäki M; Korpela K; Marttila R; Kaasinen V; Hartikainen P; Lyytinen J; Kaakkola S; Hänninen J; Löyttyniemi E; Kailajärvi M; Ruokoniemi P; Ellmén J
Eur J Clin Pharmacol; 2009 May; 65(5):443-55. PubMed ID: 19229530
[TBL] [Abstract][Full Text] [Related]
6. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
[TBL] [Abstract][Full Text] [Related]
7. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
[TBL] [Abstract][Full Text] [Related]
8. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
Lew MF; Somogyi M; McCague K; Welsh M;
Int J Neurosci; 2011 Nov; 121(11):605-13. PubMed ID: 21843110
[TBL] [Abstract][Full Text] [Related]
9. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
Heikkinen H; Varhe A; Laine T; Puttonen J; Kela M; Kaakkola S; Reinikainen K
Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
[TBL] [Abstract][Full Text] [Related]
10. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A
J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
[TBL] [Abstract][Full Text] [Related]
11. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
Delea TE; Thomas SK; Hagiwara M; Mancione L
Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819
[TBL] [Abstract][Full Text] [Related]
12. 24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
Ricciardi L; Bove F; Espay KJ; Lena F; Modugno N; Poon YY; Krikorian R; Espay AJ; Fasano A
Mov Disord; 2016 Apr; 31(4):597-8. PubMed ID: 26946221
[No Abstract] [Full Text] [Related]
13. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
14. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
[TBL] [Abstract][Full Text] [Related]
15. Levodopa/carbidopa/entacapone (Stalevo).
Hauser RA
Neurology; 2004 Jan; 62(1 Suppl 1):S64-71. PubMed ID: 14718682
[TBL] [Abstract][Full Text] [Related]
16. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
Othman AA; Rosebraugh M; Chatamra K; Locke C; Dutta S
J Parkinsons Dis; 2017; 7(2):275-278. PubMed ID: 28211816
[TBL] [Abstract][Full Text] [Related]
17. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
[TBL] [Abstract][Full Text] [Related]
18. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Reichmann H; Emre M
Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
[TBL] [Abstract][Full Text] [Related]
19. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.
Giladi N; Gurevich T; Djaldetti R; Adar L; Case R; Leibman-Barak S; Sasson N; Caraco Y
Parkinsonism Relat Disord; 2021 Oct; 91():139-145. PubMed ID: 34619438
[TBL] [Abstract][Full Text] [Related]
20. Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers.
Nyholm D; Ehrnebo M; Lewander T; Trolin CG; Bäckström T; Panagiotidis G; Spira J; Nyström C; Aquilonius SM
Acta Neurol Scand; 2013 Feb; 127(2):124-32. PubMed ID: 22762460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
